ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 211 - 225 of 5996 products
AstraZeneca Signs $26.5 Million Deal to Build Production Line in China for Type-2 Diabetes Drug
$5.00
Available
CARsgen Cleared to Stage China Trial of CAR-T for Hepatocellular Carcinoma
$5.00
Available
Lee’s Pharma in $138 Million Deal for China Rights to Heart Failure Treatment
$5.00
Available
Adagene Reports Positive Early Results from its anti-CTLA-4 for Colorectal Cancer
$5.00
Available
Chipscreen NewWay Starts China Trial of PD-1/CD40 Bispecific for Solid Tumor Cancers
$5.00
Available
Henlius In-licenses Novel ESR1 Antagonist Therapy for Breast Cancer in $58 Million Deal
$5.00
Available
WuXi Biologics to Discover mAbs for BioNTech for $20 Million Upfront
$5.00
Available
GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate
$5.00
Available
Bayer Joins $162 Million Round for Ji Xing; Has Preferential Rights for In-Licensings
$5.00
Available
OnCusp Completes $100 Million Series A Round for In-Licensed Cancer Candidates
$5.00
Available
Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal
$5.00
Available
Insilico Sells Global Rights for KAT6A Inhibitor to Menarini in $500 Million Deal
$5.00
Available
Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis
$5.00
Available
Tenacia Acquires China Rights to Tremor Therapy from Praxis in $279 Million Deal
$5.00
Available
Biocytogen Sells Option for HER2/TROP2 Bispecific ADC to Radiance Biopharma
$6.00
Available